Mo Amin is the Vice President of Patient Access, Government Affairs & Pricing at AstraZeneca Canada Inc., one of Canada’s leading biopharmaceutical companies. Mo brings to the position more than 25 years’ experience in the biopharmaceutical industry, including extensive experience within the areas of Market Access, Medical Affairs, Health Economics and Real World Evidence (RWE).
His career spans roles in academia and both the private and public sector. Among some of the positions Mo has held include Adjunct Professor, Department of Medicine – University of Ottawa; Scientific Advisor – Common Drug Review (CDR) and Canadian Agency for Drugs and Technologies in Health (CADTH); Director of Health Economics, Pricing & Reimbursement with Bristol-Myers Squibb in Canada and the U.S.; and Regional Head for Global Health Economics, Epidemiology & RWE – Intercontinental Region, Amgen.
Prior to joining AstraZeneca, Mo was Regional Head & VP of Medical Access at Sanofi, leading medical, access and evidence generation strategies for Asia-Pacific, Africa, Middle East and China regions.
Mo is a trained medical graduate with a Master’s in Economics from the University of Essex and a PhD in Health Economics and Policy from the University of London.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
The Patient perspective – Instil the Patients’ Voice into Your Market Access Strategy to Enhance Your Product’s Success
Involving patient groups has become a cornerstone to the success of new product launches. Advance the validity of your R&D results, RWE and your market access strategy by incorporating the patient voice from the earliest possible stage of development. Create a blueprint to:
- Initiate greater collaboration with patient groups earlier on to engage them within the boundaries of compliance
- Understand the benefits of involving patients in the trial design stage
- Gain early insight into how patients react to your product that can enhance your success throughout your development cycle, submission processes and beyond to patient support
Instil the patients’ voice into your R&D to advance your market access strategy
Day 3: Oct 8, 2020